Looking for new targets for prostate cancer therapy: Nuclear factor kappa B and CXCR4 co-expression in prostate specimens from RTOG-8610

14578 Background: The transcription factor Nuclear Factor-kappa B (NFκB) promotes the production of angiogenic, anti-apoptotic and prometastatic factors that are involved in carcinogenesis. The chemokine receptor CXCR4, which is under the control of NFκB, has been implicated in regulating metastasis of breast, pancreatic, and prostate cancer. This retrospective cohort study evaluated the frequency and co-expression of NFκB and CXCR4 in human prostate cancer specimens. Methods: Paraffin embedded samples from a subset of patients in the RTOG 8610 trial underwent immunohistochemical staining for NFκB and CXCR4. This study compared radiotherapy plus hormonal therapy to radiation therapy alone. The amount of NFκB and CXCR4 was scored by a blinded pathologist for the percentage of cells stained (0 to 100%) and staining intensity (0 to 3+). Results: NFκB and CXCR4 status was determined for 55 and 63 patients, respectively. Both NFκB and CXCR4 status were available for 51 of these patients. Of these, 51% were 2/3...